Top Story

Biguanides, liraglutide reduced CVD risk in type 2 diabetes

September 24, 2014

Patients with type 2 diabetes treated with biguanides and liraglutide have a reduced risk for ischemic heart disease, heart failure and stroke, according to research presented at the 50th European Association for the Study of Diabetes Annual Meeting.

The effect of liraglutide (Victoza, Novo Nordisk) was not linked to biochemical values, including cholesterol or glucose control, in patients with type 2 diabetes who subsequently experienced the cardiovascular composite endpoint in a retrospective, nested, case-control study by Danish researchers.

figure Meeting News Coverage

Higher plasma levels linked to CV complications in type 1 diabetes

September 18, 2014
Cardiovascular complications are associated with higher plasma levels in patients with type 1 diabetes, according to a presenter at the 50th European Association for the…
In the Journals

Age, diabetes duration increases risk for macrovascular complications

September 12, 2014
For patients with type 2 diabetes, macrovascular events and death are associated with age or age at diagnosis and diabetes duration, according to research published in…
figure In the Journals

Clopidogrel response impaired among patients with diabetes, CAD

September 4, 2014
Patients with diabetes and CAD experienced an impaired response to platelet P2Y12 receptor antagonist clopidogrel compared with those without diabetes in a recent…
CME
figure

Practical Lipidology: 2013

This activity is supported by an educational grant from Genentech.

The rise in the prevalence of obesity in the last few decades and its growing impact on health has driven the…
More »
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »

Filter By:

Meeting News Coverage

Biguanides, liraglutide reduced CVD risk in type 2 diabetes

September 24, 2014
Patients with type 2 diabetes treated with biguanides and liraglutide have a reduced risk for ischemic heart disease, heart failure and stroke…
figure Meeting News Coverage

Higher plasma levels linked to CV complications in type 1 diabetes

September 18, 2014
Cardiovascular complications are associated with higher plasma levels in patients with type 1 diabetes, according to a presenter at the 50th European…
In the Journals

Age, diabetes duration increases risk for macrovascular complications

September 12, 2014
For patients with type 2 diabetes, macrovascular events and death are associated with age or age at diagnosis and diabetes duration, according to…
figure In the Journals

Clopidogrel response impaired among patients with diabetes, CAD

September 4, 2014
Patients with diabetes and CAD experienced an impaired response to platelet P2Y12 receptor antagonist clopidogrel compared with those without…
In the Journals

Insulin use, dialysis predicted poor wound healing after endovascular therapy

August 28, 2014
Patients undergoing endovascular therapy for critical limb ischemia were significantly more likely to have non-healing wounds if they used insulin…
figure In the Journals Perspective

DEFINITIVE LE published: Directional atherectomy effective regardless of diabetes status

August 27, 2014
Patients with or without diabetes who underwent directional atherectomy for peripheral artery disease experienced similar rates of primary patency at…

Nutrition education lacking in medical training

August 26, 2014
A group of physicians are questioning how well doctors can provide nutrition information and counseling to patients, particularly those with CVD…

AHA and ADA: CV risk assessment, monitoring essential for patients with type 1 diabetes

August 21, 2014
A greater understanding of the pathophysiology, risk prediction and treatment of CVD in patients with type 1 diabetes is essential to minimize the…
figure FDA News

FDA opens dialogue on interim results of CV safety in diabetes drug trials

August 12, 2014
The FDA has launched a dialogue on how to handle confidentiality of the interim results for cardiovascular outcomes in diabetes treatment trials…
In the Journals

Knowing modifiable risk factors may reduce CV death in type 2 diabetes

July 9, 2014
Determining vascular calcification and modifiable risk factors for heart disease could provide patients with type 2 diabetes the insight needed to…
More Headlines »